These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 24332244

  • 1. Prescribing practices for intravenous aminoglycosides in UK cystic fibrosis clinics: a questionnaire survey.
    Smyth AR, Campbell EL.
    J Cyst Fibros; 2014 Jul; 13(4):424-7. PubMed ID: 24332244
    [Abstract] [Full Text] [Related]

  • 2. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA.
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [Abstract] [Full Text] [Related]

  • 3. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD002009. PubMed ID: 20091528
    [Abstract] [Full Text] [Related]

  • 4. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Tan KH.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD002009. PubMed ID: 16855982
    [Abstract] [Full Text] [Related]

  • 5. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2014 Feb 04; (2):CD002009. PubMed ID: 24497229
    [Abstract] [Full Text] [Related]

  • 6. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N, Bell S, Greville H, Doecke C.
    Intern Med J; 2009 Aug 04; 39(8):527-31. PubMed ID: 19220547
    [Abstract] [Full Text] [Related]

  • 7. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA, Nagel JL.
    Pharmacotherapy; 2010 Jan 04; 30(1):95-108. PubMed ID: 20030477
    [Abstract] [Full Text] [Related]

  • 8. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Tan K, Bunn H.
    Cochrane Database Syst Rev; 2000 Jan 04; (4):CD002009. PubMed ID: 11034740
    [Abstract] [Full Text] [Related]

  • 9. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD002009. PubMed ID: 22336782
    [Abstract] [Full Text] [Related]

  • 10. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
    Phillips JA, Bell SC.
    Intern Med J; 2001 Feb 15; 31(1):23-6. PubMed ID: 11478352
    [Abstract] [Full Text] [Related]

  • 11. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP.
    Pediatrics; 2004 Jul 15; 114(1):e111-8. PubMed ID: 15231982
    [Abstract] [Full Text] [Related]

  • 12. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG.
    Pediatr Pulmonol; 2013 Nov 15; 48(11):1047-61. PubMed ID: 24000183
    [Abstract] [Full Text] [Related]

  • 13. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Sutton L, Clayton D, Arch B, Tanajewski Ł, Berdunov V, Williamson PR.
    Health Technol Assess; 2021 Nov 15; 25(65):1-128. PubMed ID: 34806975
    [Abstract] [Full Text] [Related]

  • 14. Survey of acute renal failure in patients with cystic fibrosis in the UK.
    Bertenshaw C, Watson AR, Lewis S, Smyth A.
    Thorax; 2007 Jun 15; 62(6):541-5. PubMed ID: 17234661
    [Abstract] [Full Text] [Related]

  • 15. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
    Ochs MA, Dillman NO, Caverly LJ, Chaffee VD.
    Pediatr Pulmonol; 2021 Dec 15; 56(12):3634-3643. PubMed ID: 33983680
    [Abstract] [Full Text] [Related]

  • 16. Exploring the Relationship between FEV1 Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies.
    Hoff BM, Scheetz MH, Jain M, Cullina JF, Rhodes NJ.
    Pharmacotherapy; 2020 Jun 15; 40(6):584-591. PubMed ID: 32259317
    [Abstract] [Full Text] [Related]

  • 17. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA.
    J Cyst Fibros; 2021 Mar 15; 20(2):288-294. PubMed ID: 33341407
    [Abstract] [Full Text] [Related]

  • 18. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D, Stableforth D.
    Drugs; 2000 Nov 15; 60(5):1053-64. PubMed ID: 11129122
    [Abstract] [Full Text] [Related]

  • 19. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
    Elphick HE, Scott A.
    Cochrane Database Syst Rev; 2016 Dec 01; 12(12):CD002007. PubMed ID: 27907224
    [Abstract] [Full Text] [Related]

  • 20. Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections.
    Paradisi F, Corti G.
    J Chemother; 1995 Aug 01; 7(4):338-43. PubMed ID: 8568544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.